1. Introduction

   EditorialNotes Pages: 655 - 655

2. Jubilee message

   Legacy Pages: 656 - 656

3. Nicotine and sympathetic neurotransmission

   • Markus Haass
   • Wolfgang Kübler

   Applied Pharmacology Pages: 657 - 665

4. Effects of KT-362, a sarcolemmal and intracellular calcium antagonist, on calcium transients of cultured neonatal rat ventricular cells: A comparison with gallopamil and ryanodine

   • Youichi Tatsukawa
   • Makoto Arita

   Applied Pharmacology Pages: 667 - 675

5. Heart rate and heart rate variability, a pharmacological target

   • Bernard Swynghedauw
   • Sylvain Jasson
   • François Carré

   Applied Pharmacology Pages: 677 - 685

6. Clinical efficacy of propantheline bromide in neurocardiogenic syncope: Pharmacodynamic implications

   • John C. L. Yu
   • Ruey J. Sung

   Applied Pharmacology Pages: 687 - 692

7. Current and newer approaches in the drug treatment of congestive heart failure

   • P. A. van Zwieten

   Congestive Heart Failure Pages: 693 - 702

8. Intropic agents in the treatment of heart failure: Despair or hope?

   • Shigetake Sasayama

   Congestive Heart Failure Pages: 703 - 709

9. Medical treatment of heart failure: The Canadian Cardiovascular Society's Consensus Conference revisited

   • Pascal Vantrimpont
   • Jean L. Rouleau

   Congestive Heart Failure Pages: 711 - 716

10. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans

    • Gabor Sütsch
    • Osmund Bertel
    • Wolfgang Kiowski

    Congestive Heart Failure Pages: 717 - 725

11. The case for low-dose aspirin for the prevention of myocardial infarction: But how low is low?

    • Werner Förster
    • James Roy Parratt

    Coronary Artery Disease Pages: 727 - 734

12. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure

    • Udho Thadani

    Coronary Artery Disease Pages: 735 - 742

13. Hemostatic variables and ischemic cardiovascular disease: Do we need a concerted effort for more profitable future clinical investigations?

    • Giovanni Di Minno
    • Francesco Paolo Mancini
    • Maurizio Margaglione

    Coronary Artery Disease Pages: 743 - 749

14. The risk and cost-effective individual patient management: The challenge of a new generation of clinical trials

    • Attilio Maseri
    • Domenico Cianflone
    • Filippo Crea

    Trial Design Pages: 751 - 758

15. Alternatives to mega-trials in cardiovascular disease

    • J. R. Hampton

    Trial Design Pages: 759 - 765

16. Controversies in preconditioning

    • Jan Willem de Jong
    • Robert de Jonge
    • Silvia Bradamante

    Preconditioning Pages: 767 - 773

17. Does protein kinase C play a pivotal role in the mechanisms of ischemic preconditioning?

    • Ben C. G. Gho
    • Yvonne E. G.
    • Pieter D. Verdouw

    Preconditioning Pages: 775 - 786

18. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia

    • Sylvie Perreault
    • Vivian H. Hamilton
    • Steven Grover

    Lipids Pages: 787 - 794

19. Endothelin, vascular hypertrophy, and hypertension

    • Clive Rosendorff

    Hypertension Pages: 795 - 802

20. Effects of antihypertensive drugs on various aspects of renal function

    • Peter W. de Leeuw
    • Willem H. Birkenhäger

    Hypertension Pages: 803 - 808